Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Shareholders held by Maravai LifeSciences Holdings, Inc. on May 26, 2026. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (March 27, 2026), the Company had 258,180,170 shares of common stock outstanding. A quorum was established with 236,082,968 shares present. All three proposals submitted to shareholders were approved:
- Proposal 1 (Election of Directors): Bernd Brust, Gregory T. Lucier, and Luke Marker were elected to three-year terms expiring in 2029. Each nominee received over 179 million votes in favor.
- Proposal 2 (Auditor Ratification): Shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2026. Votes were 234,492,897 For, 1,246,939 Against, and 343,132 Abstentions.
- Proposal 3 (Executive Compensation): Shareholders approved the compensation of named executive officers on a non-binding advisory basis. Votes were 200,054,156 For, 2,457,403 Against, and 312,439 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of shareholder voting results.
Investor Verification Checklist
- Verify the composition of the Board of Directors for the 2026-2029 term.
- Confirm the engagement of Deloitte & Touche LLP for the 2026 fiscal year audit.
- Review the proxy statement referenced in Proposal 3 for details on executive compensation packages.
- Check subsequent filings (e.g., 10-K or 10-Q) for the financial metrics absent in this 8-K.